Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II)

Biomaterials

Volumn 32, Issue 30, 2011, Pages 7732-7739

  Xiao, Haihua ^a,b   Qi, Ruogu ^a,b   Liu, Shi ^a,b   Hu, Xiuli ^a   Duan, Taicheng ^a   Zheng, Yonghui ^a   Huang, Yubin ^a   Jing, Xiabin ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cancer therapy; Cisplatin; Drug delivery; Platinum anti tumor drugs; Polymer drug conjugate

Indexed keywords

AMINO GROUP; AMPHIPHILICS; CANCER THERAPY; CANCEROUS CELLS; CIS-PLATIN; CLINICAL APPLICATION; DIRECT DETERMINATION; DRUG RELEASE; FLUORESCENCE IMAGING; HPLC ICP MS; IN-VITRO; MTT ASSAYS; NANOMICELLES; POLYMER CARRIER; POLYMER-DRUG CONJUGATE; TUMOR CELLS;

BIODEGRADABLE POLYMERS; BLOCK COPOLYMERS; CONJUGATED POLYMERS; DRUG DELIVERY; DRUG PRODUCTS; MICELLES; MOLECULAR BIOLOGY; MOTION PICTURE EXPERTS GROUP STANDARDS; PLATINUM; TUMORS;

PLATINUM COMPOUNDS;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN DERIVATIVE; CISPLATIN II; CISPLATIN IV; NANOCARRIER; POLYMER; PRODRUG; UNCLASSIFIED DRUG; CISPLATIN; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENE GLYCOL; PLATINUM COMPLEX;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TUMOR LEVEL; ENDOCYTOSIS; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MICELLE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; CHEMISTRY; NEOPLASM; TUMOR CELL LINE;

CELL LINE, TUMOR; CISPLATIN; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; PRODRUGS;

EID: 80051545872     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.06.072     Document Type: Article

References (27)

1. Madias N.E., Harrington J.T. Platinum nephrotoxicity. Am J Med 1978, 65:307-314.
2. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
3. Ekborn A., Laurell G., Andersson A., Wallin I., Eksborg S., Ehrsson H. Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig. Hearing Res 2000, 140:38-44.
4. Giandomenico C.M., Abrams M.J., Murrer B.A., Vollano J.F., Rheinheimer M.I., Wyer S.B., et al. Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entrée into orally active platinum(IV) antitumor agents. Inorg Chem 1995, 34:1015-1021.
5. Reithofer M., Galanski M., Roller A., Keppler B.K. An entry to novel platinum complexes: carboxylation of dihydroxoplatinum(IV) complexes with succinic anhydride and subsequent derivatization. Eur J Inorg Chem 2006, 13:2612-2617.
6. Reithofer M.R., Valiahdi S.M., Jakupec M.A., Arion V.B., Egger A., Galanski M., et al. Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem 2007, 50:6692-6699.
7. Hall M.D., Mellor H.R., Callaghan R., Hambley T.W. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem 2007, 50:3403-3411.
8. Choi S., Filotto C., Bisanzo M., Delaney S., Lagasee D., Whitworth J.L., et al. Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 1998, 37:2500-2504.
9. Hall M.D., Hambley T.W. Platinum(IV) antitumor compounds: their bioinorganic chemistry. Coord Chem Rev 2002, 232:49-67.
10. Shi T.S., Berglund J., Elding L.I. Kinetics and mechanism for reduction of trans-dichlorotetracyanoplatinate(IV) by thioglycolic acid, l-cysteine, dl-penicillamine, and glutathione in aqueous solution. Inorg Chem 1996, 35:3498-3503.
11. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001, 74:47-61.
12. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul 2001, 41:189-207.
13. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
14. Aryal S., Hu C.-M., Zhang L.F. Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2010, 4:251-258.
15. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 2010, 107:17939-17944.
16. Dhar S., Daniel W.L., Giljohann D.A., Mirkin C.A., Lippard S.J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) wareheads. J Am Chem Soc 2009, 131:14652-14653.
17. Xie Z.G., Guan H.L., Chen X.S., Lu T.C., Chen L., Hu X.L., et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release 2007, 117:210-216.
18. Xu X.Y., Zhang X.F., Wang X.H., Li Y.X., Jing X.B. Comparative study of paclitaxel physically encapsulated in and chemically conjugated with PEG-PLA. Polym Adv Technol 2009, 20:843-848.
19. Hu X.L., Liu S., Huang Y.B., Chen X.S., Jing X.B. Biodegradable block copolymer-doxorubicin conjugates via different linkages: preparation, characterization, and in vitro evaluation. Biomacromolecules 2010, 11:2094-2102.
20. Ribaud P., Gouveia J., Misset J.L., Mathé G. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP). Oncology 1986, 43:78-82.
21. Kurata T., Tamura T., Sasaki Y., Fujii H., Negoro S., Fukuoka M., et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000, 30:377-384.
22. Latif T., Wood L., Connell C., Smith D.C., Vaughn D., Lebwohl D., et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005, 23:79-84.
23. Ray G.B., Chakraborty I., Moulik S.P. Pyrene absorption can be a convenient method for probing critical micellar concentration (cmc) and indexing micellar polarity. J Colloid Interf Sci 2006, 294:248-254.
24. Hann S., Koellensperger G., Stefánka Z.S., Stingeder G., Fürhacker M., Buchberger W., et al. Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine. J Anal Atom Spectrom 2003, 18:1391-1395.
25. Galettis P., Carr J.L., Paxton J.W., McKeage M.J. Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal Atom Spectrom 1999, 14:953-956.
26. Duong H.T., Huynh V.T., de Souza P., Stenzel M.H. Core-cross-linked micelles synthesized by clicking bifunctional Pt(IV) anticancer drugs to isocyanates. Biomacromolecules 2010, 11:2290-2299.
27. Feazell R.P., Nakayama-Ratchford N., Dai H., Lippard S.J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc 2007, 129:8438-8439.